Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 11/20 | 0.55 |
| ▸ | CRBN | Q96SW2 | 11/20 | 0.55 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.42 |
| ▸ | FPR3 | P25089 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30706246 | 1.00 | DDB1 (0.55) | DDB1CRBNACKR3KDM1AGSPT1 | |
| SCHEMBL30705982 | 0.90 | DDB1 (0.54) | DDB1CRBNACKR3KDM1AHTR6 | |
| SCHEMBL30705882 | 0.90 | DDB1 (0.54) | DDB1CRBNACKR3KDM1AHTR6 | |
| SCHEMBL27039465 | 0.89 | DDB1 (0.58) | DDB1CRBNFPR3FPR2 | |
| SCHEMBL31232850 | 0.84 | CRBN (0.63) | DDB1CRBN | |
| SCHEMBL30705914 | 0.83 | DDB1 (0.70) | DDB1CRBNACKR3KDM1AHTR6 | |
| SCHEMBL30706148 | 0.83 | DDB1 (0.70) | DDB1CRBNACKR3KDM1AHTR6 | |
| SCHEMBL30706234 | 0.83 | DDB1 (0.57) | DDB1CRBN | |
| SCHEMBL21605819 | 0.80 | ACKR3 (0.57) | ACKR3KDM1AHTR6FPR3FPR2 | |
| SCHEMBL21605820 | 0.80 | ACKR3 (0.57) | ACKR3KDM1AHTR6FPR3FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270191-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-08-28 | — | — | US | disclosed |
| EP-4536649-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023244918-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270191-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | DDB1 141/4885CRBN 756/4885ACKR3 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.